Myriad Genetics Launches Prolaris + AI Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 26 2026
0mins
Myriad Genetics announced the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology.1-4 This combination helps identify if a patient is safe for active surveillance, or AS, and how refinement of AS intensity can be personalized.4-8 This new paradigm in patient care builds upon technology from PATHOMIQ AI, a digital pathology AI platform company. The Prolaris + AI test is the only test where AS metrics on patient results were built on studies with previously diagnosed, untreated patient cohorts.1-4 The Prolaris + AI test will continue to help doctors identify patients who are safe for single-modal treatment. AS is recommended by major clinical guidelines for men with low- and favorable intermediate-risk prostate cancer, but follow-up can vary widely by the limited ability of traditional clinical and pathology tools to predict short-term tumor behavior to help guide surveillance intensity. The Prolaris + AI Test was developed to address this gap by providing the likelihood of a higher Gleason score at next biopsy to help clinicians tailor AS protocols.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYGN
Wall Street analysts forecast MYGN stock price to rise
5 Analyst Rating
2 Buy
2 Hold
1 Sell
Hold
Current: 4.690
Low
4.00
Averages
7.38
High
9.00
Current: 4.690
Low
4.00
Averages
7.38
High
9.00
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Myriad Genetics Appoints New Chief Technology Officer
- New CTO Appointment: Myriad Genetics appointed Raj Jampa as Chief Technology Officer effective June 1, 2026, aiming to leverage his technology leadership to scale business operations and accelerate innovation, thereby enhancing customer experience and supporting growth strategies.
- Technology Strategy Execution: Jampa will oversee the strategy and execution of Myriad's technology organization, particularly focusing on leveraging AI to drive efficiency and effectiveness, which will directly impact the company's operational model and market competitiveness.
- Rich Industry Experience: Prior to joining Myriad, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences, and Genomic Health, where he successfully led large-scale transformation initiatives, indicating his capability to modernize technology infrastructure and advance Myriad's growth strategy.
- Forward-Looking Statements: Myriad Genetics stated that Jampa's leadership will be crucial in strengthening the digital technology foundation, enhancing customer experience, and supporting the next phase of growth and value creation, reflecting the company's positive outlook on future developments.
See More
Myriad Genetics Unveils New Data on MRD Testing Across Cancer Types
- Clinical Data Showcase: Myriad Genetics will present data from six poster sessions demonstrating the utility of its Precise MRD™ test across various cancer types, particularly highlighting a 97% baseline detection rate from the MONSTAR-SCREEN-3 study, underscoring the test's significance in early cancer recurrence risk assessment.
- Ultra-Sensitive Detection Advantage: The study reveals that patients who were ctDNA-positive one month post-surgery had significantly worse disease-free survival compared to ctDNA-negative patients, emphasizing the potential value of ultra-sensitive ctDNA detection in clinical decision-making and possibly paving the way for new detection standards.
- Applicability Across Cancer Types: Myriad's research spans ovarian, gastric, head and neck cancers, and sarcoma, showcasing the clinical utility of ctDNA as a biomarker for recurrence and therapy response, further solidifying its role in precision medicine.
- Industry Expert Interaction: Myriad will offer attendees the opportunity to engage with Chief Scientific Officer Dale Muzzey during the conference, providing insights into the technical details of the Precise MRD test and its clinical evidence across multiple solid tumors, fostering knowledge sharing and collaboration within the industry.
See More
Myriad Genetics Launches Prolaris + AI Test for Prostate Cancer Prognosis
- New Test Launch: Myriad Genetics has announced the launch of the Prolaris + AI test, designed to enhance the accuracy of prostate cancer prognosis prediction by integrating clinical-pathological features with AI digital pathology technology, expected to be available by the end of May 2026.
- Strong Market Demand: With over 300,000 new prostate cancer cases diagnosed annually in the U.S., early treatment is crucial for survival, making this test a timely solution to meet the urgent need for precision medicine and assist physicians in developing more effective monitoring strategies.
- Technological Innovation: The test leverages PATHOMIQ AI technology to provide a clinical cell-cycle risk (CCR) score and utilizes an AI model to predict the likelihood of higher Gleason scores at subsequent check-ups, thereby enhancing the guidance capabilities of existing pathology tools.
- Validation Study Support: The AI model, trained on biopsy histopathology images from 998 patients and validated in 296 patients, demonstrated that the AI-Gleason Upgrade Risk (AI-GUR) is a statistically significant independent predictor of Gleason score upgrades, further enhancing the test's efficacy.
See More
Identifying Potentially Profitable Stocks
- Impinj Risk Analysis: Impinj (PI) has a trailing 12-month GAAP operating margin of -1.8%, with projected sales growth of only 9.3% over the next year indicating sluggish demand, and its forward P/E ratio of 64.7 suggests overvaluation, posing a risk of value destruction for investors.
- Myriad Genetics Financial Struggles: Myriad Genetics (MYGN) reports a GAAP operating margin of -46.9% over the past year, with annual revenue growth of just 3.5%, significantly below healthcare sector standards, and negative returns on capital indicate management's failure to generate profits while expanding, warranting caution from investors.
- Gevo Growth Potential: Gevo (GEVO) has achieved an impressive 19% annual revenue growth over the past decade, despite a GAAP operating margin of -2.9%, as its EBITDA profits and efficiency have improved due to fixed cost leverage, highlighting its competitive position in the renewable fuel market.
- Market Watch Recommendations: While Impinj and Myriad Genetics face significant challenges, Gevo's performance suggests potential long-term growth opportunities, making it a stock to watch for investors interested in sustainable aviation fuel market share expansion.
See More
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing
- Collaborative Awareness Campaign: Myriad Genetics has partnered with actress Jackie Tohn to raise awareness about the significance of the MyRisk® Hereditary Cancer Test, particularly after Tohn discovered her BRCA1 gene variant, enabling proactive health management.
- Risk Assessment Insights: Tohn learned through genetic testing that she had an 85% risk of developing breast cancer and a 65% risk of ovarian cancer, underscoring the critical role of hereditary cancer screening in early detection and prevention, potentially saving lives.
- Comprehensive Testing Scope: The MyRisk® test evaluates 63 genes across 11 cancer types, with its breast cancer risk assessment being twice as predictive as personal and family history alone, highlighting its importance in precision medicine.
- Clinical Relevance: More than one in four women in OB-GYN settings meet the clinical criteria for hereditary cancer testing, with Ashkenazi Jewish individuals having a 1 in 40 chance of carrying BRCA1/2 mutations, emphasizing the need for targeted testing in specific populations.
See More
Myriad Genetics Reports Q1 2026 Earnings Miss
- Earnings Miss: Myriad Genetics reported Q1 2026 revenue of $200.4 million, falling short of expectations by approximately $2 million, despite a 2% year-over-year growth, which could not offset the impact of stable test volumes, leading to a nearly 20% drop in stock price.
- Mixed Business Growth: The Cancer Care and Mental Health units achieved year-over-year test volume growth of 13% and 7%, generating revenues of $120.2 million and $38.3 million respectively, indicating strong performance in these areas; however, Prenatal Health test volumes declined by about 12%, resulting in a 15% drop in product revenue.
- Slight Margin Decline: Although the adjusted gross margin decreased from 69.0% to 68.8%, the adjusted loss per share reached $0.09, tripling from the previous year and exceeding consensus by $0.02, reflecting challenges in cost management.
- Reaffirmed Outlook: CEO Sam Raha noted decisive steps taken to address the Prenatal Health business, expecting improved performance in the latter half of 2026, while reaffirming the revenue outlook of $860 million to $880 million for 2026, demonstrating confidence in future performance.
See More
Myriad Genetics Appoints New Chief Technology Officer
- New CTO Appointment: Myriad Genetics appointed Raj Jampa as Chief Technology Officer effective June 1, 2026, aiming to leverage his technology leadership to scale business operations and accelerate innovation, thereby enhancing customer experience and supporting growth strategies.
- Technology Strategy Execution: Jampa will oversee the strategy and execution of Myriad's technology organization, particularly focusing on leveraging AI to drive efficiency and effectiveness, which will directly impact the company's operational model and market competitiveness.
- Rich Industry Experience: Prior to joining Myriad, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences, and Genomic Health, where he successfully led large-scale transformation initiatives, indicating his capability to modernize technology infrastructure and advance Myriad's growth strategy.
- Forward-Looking Statements: Myriad Genetics stated that Jampa's leadership will be crucial in strengthening the digital technology foundation, enhancing customer experience, and supporting the next phase of growth and value creation, reflecting the company's positive outlook on future developments.
See More
Myriad Genetics Unveils New Data on MRD Testing Across Cancer Types
- Clinical Data Showcase: Myriad Genetics will present data from six poster sessions demonstrating the utility of its Precise MRD™ test across various cancer types, particularly highlighting a 97% baseline detection rate from the MONSTAR-SCREEN-3 study, underscoring the test's significance in early cancer recurrence risk assessment.
- Ultra-Sensitive Detection Advantage: The study reveals that patients who were ctDNA-positive one month post-surgery had significantly worse disease-free survival compared to ctDNA-negative patients, emphasizing the potential value of ultra-sensitive ctDNA detection in clinical decision-making and possibly paving the way for new detection standards.
- Applicability Across Cancer Types: Myriad's research spans ovarian, gastric, head and neck cancers, and sarcoma, showcasing the clinical utility of ctDNA as a biomarker for recurrence and therapy response, further solidifying its role in precision medicine.
- Industry Expert Interaction: Myriad will offer attendees the opportunity to engage with Chief Scientific Officer Dale Muzzey during the conference, providing insights into the technical details of the Precise MRD test and its clinical evidence across multiple solid tumors, fostering knowledge sharing and collaboration within the industry.
See More
Myriad Genetics Launches Prolaris + AI Test for Prostate Cancer Prognosis
- New Test Launch: Myriad Genetics has announced the launch of the Prolaris + AI test, designed to enhance the accuracy of prostate cancer prognosis prediction by integrating clinical-pathological features with AI digital pathology technology, expected to be available by the end of May 2026.
- Strong Market Demand: With over 300,000 new prostate cancer cases diagnosed annually in the U.S., early treatment is crucial for survival, making this test a timely solution to meet the urgent need for precision medicine and assist physicians in developing more effective monitoring strategies.
- Technological Innovation: The test leverages PATHOMIQ AI technology to provide a clinical cell-cycle risk (CCR) score and utilizes an AI model to predict the likelihood of higher Gleason scores at subsequent check-ups, thereby enhancing the guidance capabilities of existing pathology tools.
- Validation Study Support: The AI model, trained on biopsy histopathology images from 998 patients and validated in 296 patients, demonstrated that the AI-Gleason Upgrade Risk (AI-GUR) is a statistically significant independent predictor of Gleason score upgrades, further enhancing the test's efficacy.
See More
Identifying Potentially Profitable Stocks
- Impinj Risk Analysis: Impinj (PI) has a trailing 12-month GAAP operating margin of -1.8%, with projected sales growth of only 9.3% over the next year indicating sluggish demand, and its forward P/E ratio of 64.7 suggests overvaluation, posing a risk of value destruction for investors.
- Myriad Genetics Financial Struggles: Myriad Genetics (MYGN) reports a GAAP operating margin of -46.9% over the past year, with annual revenue growth of just 3.5%, significantly below healthcare sector standards, and negative returns on capital indicate management's failure to generate profits while expanding, warranting caution from investors.
- Gevo Growth Potential: Gevo (GEVO) has achieved an impressive 19% annual revenue growth over the past decade, despite a GAAP operating margin of -2.9%, as its EBITDA profits and efficiency have improved due to fixed cost leverage, highlighting its competitive position in the renewable fuel market.
- Market Watch Recommendations: While Impinj and Myriad Genetics face significant challenges, Gevo's performance suggests potential long-term growth opportunities, making it a stock to watch for investors interested in sustainable aviation fuel market share expansion.
See More
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing
- Collaborative Awareness Campaign: Myriad Genetics has partnered with actress Jackie Tohn to raise awareness about the significance of the MyRisk® Hereditary Cancer Test, particularly after Tohn discovered her BRCA1 gene variant, enabling proactive health management.
- Risk Assessment Insights: Tohn learned through genetic testing that she had an 85% risk of developing breast cancer and a 65% risk of ovarian cancer, underscoring the critical role of hereditary cancer screening in early detection and prevention, potentially saving lives.
- Comprehensive Testing Scope: The MyRisk® test evaluates 63 genes across 11 cancer types, with its breast cancer risk assessment being twice as predictive as personal and family history alone, highlighting its importance in precision medicine.
- Clinical Relevance: More than one in four women in OB-GYN settings meet the clinical criteria for hereditary cancer testing, with Ashkenazi Jewish individuals having a 1 in 40 chance of carrying BRCA1/2 mutations, emphasizing the need for targeted testing in specific populations.
See More
Myriad Genetics Reports Q1 2026 Earnings Miss
- Earnings Miss: Myriad Genetics reported Q1 2026 revenue of $200.4 million, falling short of expectations by approximately $2 million, despite a 2% year-over-year growth, which could not offset the impact of stable test volumes, leading to a nearly 20% drop in stock price.
- Mixed Business Growth: The Cancer Care and Mental Health units achieved year-over-year test volume growth of 13% and 7%, generating revenues of $120.2 million and $38.3 million respectively, indicating strong performance in these areas; however, Prenatal Health test volumes declined by about 12%, resulting in a 15% drop in product revenue.
- Slight Margin Decline: Although the adjusted gross margin decreased from 69.0% to 68.8%, the adjusted loss per share reached $0.09, tripling from the previous year and exceeding consensus by $0.02, reflecting challenges in cost management.
- Reaffirmed Outlook: CEO Sam Raha noted decisive steps taken to address the Prenatal Health business, expecting improved performance in the latter half of 2026, while reaffirming the revenue outlook of $860 million to $880 million for 2026, demonstrating confidence in future performance.
See More
